DIGITAL SINGLE-USE TOTAL AND HDL CHOLESTEROL TEST

描述（改编自申请人摘要）：冠心病 (CHD)是一个重大的公共卫生问题， 每年在美国发生的袭击事件。 超过四千万人 据估计，约50%的成年人患有高脂血症， 接近美国的高胆固醇水平 年度 心血管疾病的费用由美国心脏协会估计。 协会将超过1170亿美元。 Metrika实验室将开发 数字响应总/高密度脂蛋白胆固醇测试，这是一个一次性使用， 基于同时测量两种物质的一次性测定 在一个小的手指针刺血样中， 结果 这个测试设备大约有信用卡那么大， 将结合联合收割机廉价的微电子和干试剂化学。 这种创新的测试将是非常简单的操作，并将提供 几分钟内就能显示结果。 它可以在 护理点或由在家的非专业用户进行。 这项技术将 通过提供方便和廉价的方法使患者受益， 监察降胆固醇治疗的成效及生活方式 变化，并筛选未确诊的个体， 胆固醇和低HDL-胆固醇-两者都是独立的风险 冠心病的发展因素。 拟议商业应用：不可用

DESCRIPTION (Adapted from applicant's abstract): Coronary heart disease (CHD) is a major public health problem with over 1.5 million new heart attacks each year in the United States. Over 40 million individuals have diagnosed hyperlipidemia and about 50% of adults are estimated to have borderline to high cholesterol levels in the United States. The annual cost of cardiovascular disease is estimated by the American Heart Association to be over $117 billion. Metrika Laboratories will develop the Digital Response Total/HDL Cholesterol Test which is a single-use, disposable assay based on the simultaneous measurement of both substances in a small, finger-stick blood sample to yield quantitative numerical results. The test device, which will be about the size of a credit card, will combine inexpensive microelectronics and dry reagent chemistry. This innovative test will be extremely simple to operate and will provide a digital display of results in a few minutes. It can be used at the point-of-care or by the lay user in the home. This technology will benefit patients by providing a convenient and inexpensive method to monitor the effectiveness of cholesterol- lowering treatment and lifestyle changes and to screen undiagnosed individuals for both elevated total cholesterol and low HDL-cholesterol - both of which are independent risk factors for the development of CHD. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE